As the popularity of glucagon-like peptide-1 (GLP-1) receptor agonists—such as semaglutide and tirzepatide—continues to skyrocket, the medical community is grappling with how these potent medications interact with elective surgical procedures. A landmark study published in the April issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS), offers a critical, nuanced look at this intersection. Specifically, the research examines how these medications influence recovery for patients undergoing abdominal panniculectomy, a common body contouring procedure following significant weight loss.
For surgeons and patients alike, the findings represent a "complex and nuanced" reality: while GLP-1 medications do not appear to spike major, life-threatening surgical risks, they do seem to alter the body’s physiological approach to wound healing in ways that demand proactive clinical management.
Main Facts: The Intersection of Surgery and Metabolic Health
Body contouring procedures, including the panniculectomy—a surgery to remove excess skin and adipose tissue from the lower abdomen—have become an essential final step for individuals who have achieved massive weight loss. However, the rise of GLP-1 medications, used for both type 2 diabetes management and medically supervised weight loss, has introduced a new variable into the surgical theater.
The study, led by Dr. Zachary Andrew Koenig of the West Virginia University School of Medicine, sought to determine if the use of these drugs creates a higher risk profile for patients. The key takeaway is that the impact is not binary. The researchers found that GLP-1 users experienced higher rates of delayed wound healing but, paradoxically, significantly lower rates of seroma (fluid accumulation under the skin).
"As GLP-1 receptor agonist medications become increasingly integrated into the care of patients undergoing body contouring, our findings suggest that these drugs may have subtle effects on wound healing, even if they don’t increase overall surgical risks," Dr. Koenig explained. This highlights a shift in the plastic surgery landscape where metabolic optimization—using drugs to reach a target weight—must now be weighed against the biological cost of altered tissue repair.
Chronology: A Decade of Data in the "GLP-1 Capital"
To reach these conclusions, the research team conducted a retrospective analysis of 373 patients who underwent panniculectomy at their medical center between 2013 and 2023. West Virginia, the site of the study, provides a unique lens through which to view this issue, as the state consistently reports some of the highest rates of GLP-1 prescriptions in the United States.
The Timeline of Integration
- 2013–2018 (Early Adoption): During the first half of the study period, GLP-1 use among surgical candidates was relatively low and primarily focused on patients with long-standing type 2 diabetes.
- 2019–2021 (The Inflection Point): As the efficacy of these drugs for weight loss became more widely recognized in clinical practice, the surgical team noted a "sharp increase" in the number of patients presenting for body contouring who were already utilizing GLP-1 therapy.
- 2022–2023 (Modern Practice): By the final years of the study, nearly 21.7% of the patient cohort was taking GLP-1 medications prior to their operation. This growth mirrors the broader national trend of these drugs becoming a standard tool for preoperative optimization.
The researchers were careful to isolate the variables by excluding patients who underwent simultaneous bariatric or hernia surgeries. This ensured that the findings reflected the physiological impact of the medication itself, rather than the metabolic stress of concurrent internal organ procedures.
Supporting Data: Dissecting the Complication Profiles
The data revealed a striking divergence in how the body reacts to surgery when a patient is on GLP-1 therapy. While general surgical outcomes remained largely stable, two specific metrics showed statistically significant deviations.
1. The Healing Paradox
The most concerning finding was the rate of delayed wound healing. Among patients utilizing GLP-1 medications, 18.5% experienced delays in the closure of surgical sites. In contrast, only 7.5% of the non-GLP-1 group faced similar challenges. This suggests that the pharmacological mechanism of these drugs—which slows gastric emptying and alters metabolic pathways—may also influence the speed at which the body produces collagen and closes incisions.
2. The Seroma Reduction
Conversely, the study identified a beneficial trend: a significant reduction in seromas. Seromas are a common, often frustrating complication in body contouring where fluid pools beneath the incision site, requiring potential drainage or re-intervention. GLP-1 users saw a seroma rate of just 4.9%, compared to 14.0% in the control group.
3. Parity in Major Complications
Crucially, the study found no significant difference between the two groups regarding:
- Wound Dehiscence: The reopening of a surgical wound.
- Infection: Rates of post-operative surgical site infections.
- Rehospitalization: The frequency with which patients required a return to the hospital for complications.
The patient demographics between the two groups were notably similar regarding Body Mass Index (BMI). However, the GLP-1 cohort was generally more likely to suffer from comorbid conditions such as hypertension and chronic obstructive pulmonary disease (COPD), which is consistent with the patient profile for which these medications are typically prescribed.
Official Responses and Clinical Perspectives
The plastic surgery community is responding to these findings with a mix of caution and optimism. The ASPS and other professional bodies have long emphasized that patient safety is the primary pillar of elective surgery.
Dr. Koenig’s team emphasizes that the study represents a "rapidly evolving clinical landscape." They argue that the data provides a necessary foundation for future guidelines. "Our findings suggest that while GLP1ra therapy does not appear to increase major surgical risk, it may affect specific aspects of healing that warrant proactive management," the authors concluded.
Plastic surgeons are now being encouraged to engage in "shared decision-making" with their patients. This involves:
- Medication Reconciliation: Surgeons are increasingly asking patients to disclose GLP-1 usage during the initial consultation.
- Perioperative Planning: If a patient is at higher risk for delayed healing, surgeons may adjust surgical techniques, such as using specialized sutures or increased tension-reduction protocols.
- Nutrition and Hydration: Given the appetite-suppressing nature of GLP-1s, surgeons are emphasizing nutritional optimization prior to surgery to ensure the body has the protein and micronutrients required for collagen synthesis and tissue repair.
Implications: The Future of Body Contouring
The implications of this study reach far beyond a single surgical procedure. As the use of GLP-1 medications becomes a standard feature of modern healthcare, the definition of a "surgical candidate" is changing.
The Need for Standardized Guidelines
Currently, there is no universally accepted protocol regarding whether patients should pause GLP-1 medications before surgery. Some surgeons advocate for a "washout period" of one to two weeks, while others express concern that stopping the medication could lead to rebound weight gain or metabolic instability. The West Virginia study provides a critical data point, but researchers acknowledge that it is only the beginning.
Future Research Frontiers
The authors highlight that the "unique mechanisms" by which GLP-1s affect soft tissue remain "not yet fully understood." Future studies must look at:
- Dosage-Response Relationships: Does the dose of the medication correlate with the severity of healing delays?
- Diverse Populations: Does the impact vary based on age, ethnicity, or the duration of time the patient has been on the medication?
- Biological Mechanisms: Molecular research into how GLP-1 receptors influence fibroblasts and immune cells at the site of a surgical incision is the next frontier.
Final Thoughts
For the millions of patients who have successfully utilized weight loss medications to reach a healthier weight, body contouring is often the final hurdle in their journey to regain confidence and mobility. This study provides a vital message: GLP-1 therapy is not a contraindication for surgery, but it is a factor that requires attention.
By acknowledging the subtle, measurable shifts in wound healing, surgeons can continue to provide high-quality care while adapting to the metabolic realities of their patients. As the medical field continues to study this "complex and nuanced interplay," the goal remains clear: safe, effective, and transformative outcomes for all patients, regardless of their metabolic journey.
For those interested in the full technical analysis, the study "Perioperative GLP-1 Receptor Agonist Use and Surgical Outcomes in Nonbariatric Abdominal Panniculectomy: A 10-Year Retrospective Analysis" is available in the April 2026 issue of Plastic and Reconstructive Surgery® (doi: 10.1097/PRS.0000000000012405).
About the Author
